<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Senderek J</submitter><funding>European Research Council</funding><funding>Medical Research Council</funding><funding>NHGRI NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>Wellcome Trust</funding><pagination>e3163-e3179</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7836667</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>95(24)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>To test the hypothesis that monogenic neuropathies such as Charcot-Marie-Tooth disease (CMT) contribute to frequent but often unexplained neuropathies in the elderly, we performed genetic analysis of 230 patients with unexplained axonal neuropathies and disease onset ≥35 years.&lt;h4>Methods&lt;/h4>We recruited patients, collected clinical data, and conducted whole-exome sequencing (WES; n = 126) and &lt;i>MME&lt;/i> single-gene sequencing (n = 104). We further queried WES repositories for &lt;i>MME&lt;/i> variants and measured blood levels of the &lt;i>MME&lt;/i>-encoded protein neprilysin.&lt;h4>Results&lt;/h4>In the WES cohort, the overall detection rate for assumed disease-causing variants in genes for CMT or other conditions associated with neuropathies was 18.3% (familial cases 26.4%, apparently</pubmed_abstract><journal>Neurology</journal><pubmed_title>The genetic landscape of axonal neuropathies in the middle-aged and elderly: Focus on &lt;i>MME&lt;/i>.</pubmed_title><pmcid>PMC7836667</pmcid><funding_grant_id>MR/N027302/2</funding_grant_id><funding_grant_id>U54 NS065712</funding_grant_id><funding_grant_id>MR/N027302/1</funding_grant_id><funding_grant_id>109915/A/15/Z</funding_grant_id><funding_grant_id>R01 NS075764</funding_grant_id><funding_grant_id>U01 HG010218</funding_grant_id><funding_grant_id>309548</funding_grant_id><funding_grant_id>MR/N010035/1</funding_grant_id><funding_grant_id>MR/N025431/2</funding_grant_id><funding_grant_id>G1000848</funding_grant_id><funding_grant_id>MR/N025431/1</funding_grant_id><funding_grant_id>U01 HG007708</funding_grant_id><pubmed_authors>Weinmann D</pubmed_authors><pubmed_authors>Abreu L</pubmed_authors><pubmed_authors>Laing NG</pubmed_authors><pubmed_authors>Schirmacher A</pubmed_authors><pubmed_authors>Rudnik-Schoneborn S</pubmed_authors><pubmed_authors>Synofzik M</pubmed_authors><pubmed_authors>Nicholson G</pubmed_authors><pubmed_authors>Windhager R</pubmed_authors><pubmed_authors>Auer-Grumbach M</pubmed_authors><pubmed_authors>Kochanski A</pubmed_authors><pubmed_authors>Lassuthova P</pubmed_authors><pubmed_authors>Ellis M</pubmed_authors><pubmed_authors>Strom TM</pubmed_authors><pubmed_authors>Marques W</pubmed_authors><pubmed_authors>De Jonghe P</pubmed_authors><pubmed_authors>Ludolph A</pubmed_authors><pubmed_authors>Schlotter-Weigel B</pubmed_authors><pubmed_authors>Lamont PJ</pubmed_authors><pubmed_authors>Iglseder S</pubmed_authors><pubmed_authors>Wagner J</pubmed_authors><pubmed_authors>Weishaupt J</pubmed_authors><pubmed_authors>Young P</pubmed_authors><pubmed_authors>Kennerson M</pubmed_authors><pubmed_authors>Fischer C</pubmed_authors><pubmed_authors>Walk D</pubmed_authors><pubmed_authors>Kinslechner K</pubmed_authors><pubmed_authors>Brenner D</pubmed_authors><pubmed_authors>Schoels L</pubmed_authors><pubmed_authors>Zuchner S</pubmed_authors><pubmed_authors>Dalton J</pubmed_authors><pubmed_authors>Herrmann DN</pubmed_authors><pubmed_authors>Braathen GJ</pubmed_authors><pubmed_authors>Hoyer H</pubmed_authors><pubmed_authors>Rebelo A</pubmed_authors><pubmed_authors>Kohler JN</pubmed_authors><pubmed_authors>Dankwa L</pubmed_authors><pubmed_authors>Petri S</pubmed_authors><pubmed_authors>Schule R</pubmed_authors><pubmed_authors>Wiessner M</pubmed_authors><pubmed_authors>Wolfgang N L</pubmed_authors><pubmed_authors>Kurth I</pubmed_authors><pubmed_authors>Drager B</pubmed_authors><pubmed_authors>Kabzinska D</pubmed_authors><pubmed_authors>Wanschitz J</pubmed_authors><pubmed_authors>Francou B</pubmed_authors><pubmed_authors>Baets J</pubmed_authors><pubmed_authors>Seeman P</pubmed_authors><pubmed_authors>Senderek J</pubmed_authors><pubmed_authors>Ravenscroft G</pubmed_authors><pubmed_authors>Deconinck T</pubmed_authors><pubmed_authors>Horvath R</pubmed_authors><pubmed_authors>Stojkovic T</pubmed_authors><pubmed_authors>Eggermann K</pubmed_authors><pubmed_authors>Beetz C</pubmed_authors><pubmed_authors>Ricci G</pubmed_authors><pubmed_authors>Ong R</pubmed_authors><pubmed_authors>Toegel S</pubmed_authors></additional><is_claimable>false</is_claimable><name>The genetic landscape of axonal neuropathies in the middle-aged and elderly: Focus on &lt;i>MME&lt;/i>.</name><description>&lt;h4>Objective&lt;/h4>To test the hypothesis that monogenic neuropathies such as Charcot-Marie-Tooth disease (CMT) contribute to frequent but often unexplained neuropathies in the elderly, we performed genetic analysis of 230 patients with unexplained axonal neuropathies and disease onset ≥35 years.&lt;h4>Methods&lt;/h4>We recruited patients, collected clinical data, and conducted whole-exome sequencing (WES; n = 126) and &lt;i>MME&lt;/i> single-gene sequencing (n = 104). We further queried WES repositories for &lt;i>MME&lt;/i> variants and measured blood levels of the &lt;i>MME&lt;/i>-encoded protein neprilysin.&lt;h4>Results&lt;/h4>In the WES cohort, the overall detection rate for assumed disease-causing variants in genes for CMT or other conditions associated with neuropathies was 18.3% (familial cases 26.4%, apparently</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-26T13:47:09.875Z</modification><creation>2022-02-11T14:05:28.723Z</creation></dates><accession>S-EPMC7836667</accession><cross_references><pubmed>33144514</pubmed><doi>10.1212/wnl.0000000000011132</doi><doi>10.1212/WNL.0000000000011132</doi></cross_references></HashMap>